AROC3-1001 is a phase 1/2, placebo controlled, dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3
Phase 2 clinical trial to begin in 2022 with participation by Cedars Sinai Medical Center, University of Utah, and City of Hope
Evonik invests in start-up to improve patient recovery after open-chest surgery
Darolutamide is developed jointly by Bayer and Orion Corporation
Ligand expects 2022 royalties of $55 million to $60 million, material sales of $40 million to $50 million, and contract revenue of $52 million to $62 million.
With this approval, Brukinsa is now approved in 44 markets as BeiGene continues to advance its global registration, including the EU, US, and Great Britain
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
Nirsevimab is the first investigational long-acting antibody designed to protect all infants for the respiratory syncytial virus season with a single dose
The capex during the last nine months has been around Rs 110 crores which is all funded through internal accruals
The device will facilitate the treatment of cerebral vasospasm following hemorrhagic stroke
Subscribe To Our Newsletter & Stay Updated
